Market research
BHC Bausch Health Companies Inc
NYSE USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 7.5
- Dividend yield
- Not available
- Beta
- 0.37
Profile
Instrument facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA0717341071
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 7.5
- Dividend yield
- Not available
- Beta
- 0.37
About
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Research context
Bausch Health Companies Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BHC discussion.
5 years, 6 months ago
Bausch Health Companies Inc is currently in a long term uptrend where the price is trading 9.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Bausch Health Companies Inc's total revenue sank by 0.5% to $2B since the same quarter in the previous year.
Its net income has increased by 89.9% to $-153M since the same quarter in the previous year.
Finally, its free cash flow grew by 108.1% to $310M since the same quarter in the previous year.
Based on the above factors, Bausch Health Companies Inc gets an overall score of 4/5.